Stocksigma LogoStocksigma Logo

Caplin Point Subsidiary Receives US FDA OAI Status for Gummidipoondi Facility

The US FDA classified the inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility at Gummidipoondi as Official Action Indicated

Caplin Point Subsidiary Receives US FDA OAI Status for Gummidipoondi Facility

Caplin Point Laboratories Ltd 路 Others (Uncategorized) 路 17 Nov 2026, 7:31 pm

Caplin Point Subsidiary Receives US FDA OAI Status for Gummidipoondi Facility The US FDA classified the inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility at Gummidipoondi as Official Action Indicated (OAI) following an unannounced audit conducted between 13th Aug'26 and 21st Aug'26, which concluded with 10 procedural observations. Caplin Point Laboratories stated that the facility continues manufacturing and product supplies with no immediate material impact on financials or operations. The company is actively working with the regulator to implement corrective and preventive actions to address the observations.

Original exchange filing (PDF)

More announcements from Caplin Point Laboratories Ltd

All Caplin Point Laboratories Ltd announcements